Keyphrases
High-risk Human Papillomavirus (HR-HPV)
100%
HPV16
65%
Human Papillomavirus Vaccine
57%
Community-randomized Trials
28%
Finland
28%
Vaccination Strategy
23%
C.trachomatis
23%
Adolescent Women
23%
Chlamydia Trachomatis Infection
23%
Cervical Atypia
23%
Oral Contraceptives
23%
Vaccine Effectiveness
23%
Quality of Life
23%
Squamous Intraepithelial Lesion
23%
Population-based
23%
Cluster Randomized Trial
23%
Cancer Population
23%
Cervical Cancer Screening
23%
Vaccination
21%
Overall Effectiveness
19%
Hepatitis B Vaccine
19%
AS04
19%
Trial Registration
12%
Herd Effect
11%
Total Effectiveness
11%
Cancer Cases
10%
Cervical Cancer
10%
Duration of Infection
9%
Oral Contraceptive Use
9%
Joint Effect
9%
Role Functioning
9%
RAND-36
9%
EQ-VAS
9%
Human Papillomavirus Types
9%
Gender Neutral
7%
Birth Cohort
7%
Older Women
7%
Unvaccinated
6%
Clinical Trials
6%
Invasive Cancer
5%
Tongue Cancer
5%
Vulvar Cancer
5%
HPV 52
5%
Vaginal Cancer
5%
Medicine and Dentistry
Wart Virus
95%
Arm
35%
Human Papillomavirus Type 16
33%
Adolescence
26%
Malignant Neoplasm
23%
Chlamydia Infection
23%
Vaccine
23%
Oral Contraceptive
23%
Cluster Randomized Trial
23%
Quality of Life
23%
Oral Contraceptive Use
16%
Cervical Cancer Screening
16%
AS04
16%
Hepatitis B Vaccine
13%
Cytotechnology
11%
Infection
10%
Condom Use
7%
Herd
7%
Disease
7%
Logistic Regression Analysis
7%
Cervical Cancer
7%
